89 related articles for article (PubMed ID: 2883271)
1. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
3. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
Ott MC; Mishra RK; Johnson RL
Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Khalil EM; Ojala WH; Pradhan A; Nair VD; Gleason WB; Mishra RK; Johnson RL
J Med Chem; 1999 Feb; 42(4):628-37. PubMed ID: 10052970
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide.
Baures PW; Ojala WH; Costain WJ; Ott MC; Pradhan A; Gleason WB; Mishra RK; Johnson RL
J Med Chem; 1997 Oct; 40(22):3594-600. PubMed ID: 9357526
[TBL] [Abstract][Full Text] [Related]
6. Effect on brain monoamines in the rat of substituted and protected analogues of the oxytocin fragment, prolyl-leucyl-glycinamide following N-terminal substitution by D- and L-pipecolic acid.
Szabó G; Kovács GL; Baláspiri L; Telegdy G
Acta Physiol Hung; 1986; 67(1):155-61. PubMed ID: 2871693
[TBL] [Abstract][Full Text] [Related]
7. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position.
Johnson RL; Rajakumar G; Mishra RK
J Med Chem; 1986 Oct; 29(10):2100-4. PubMed ID: 2876103
[TBL] [Abstract][Full Text] [Related]
8. [Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
Pan JB
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):205-8. PubMed ID: 2866940
[No Abstract] [Full Text] [Related]
9. Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring alpha,alpha-disubstituted amino acids.
Evans MC; Pradhan A; Venkatraman S; Ojala WH; Gleason WB; Mishra RK; Johnson RL
J Med Chem; 1999 Apr; 42(8):1441-7. PubMed ID: 10212130
[TBL] [Abstract][Full Text] [Related]
10. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
11. Synthetic melanocyte stimulating hormone release-inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover.
Pugsley TA; Lippmann W
Arzneimittelforschung; 1977; 27(12):2293-6. PubMed ID: 23796
[TBL] [Abstract][Full Text] [Related]
12. CNS dopamine receptors: effect of prolyl-leucyl-glycinamide and solubilization.
Mishra RK
Nutr Health; 1984; 3(3):175-87. PubMed ID: 6152723
[TBL] [Abstract][Full Text] [Related]
13. Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?
Chiu S; Wong YW; Wan YP; Chiu P; Mishra RK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):739-42. PubMed ID: 6141616
[TBL] [Abstract][Full Text] [Related]
14. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
Chiu S; Paulose CS; Mishra RK
Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
[TBL] [Abstract][Full Text] [Related]
15. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
Chiu P; Rajakumar G; Chiu S; Johnson RL; Mishra RK
Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
[TBL] [Abstract][Full Text] [Related]
16. Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
Case TC; Snider SR; Hruby VJ; Rockway T
Life Sci; 1985 Jul; 36(26):2531-7. PubMed ID: 2861549
[TBL] [Abstract][Full Text] [Related]
17. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
[TBL] [Abstract][Full Text] [Related]
18. A new orally active hypotensive peptide, N-(dibenzyloxyphosphinoyl)-L-alanyl-L-prolyl-L-proline (PAPP).
Koyama Y; Ogihara T; Kumahara Y; Hashimoto S; Yoshimoto R; Eguchi C; Kurauchi M; Yugari Y; Sakakibara S
J Hypertens Suppl; 1984 Dec; 2(3):S567-9. PubMed ID: 6599717
[TBL] [Abstract][Full Text] [Related]
19. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.
Verma V; Mann A; Costain W; Pontoriero G; Castellano JM; Skoblenick K; Gupta SK; Pristupa Z; Niznik HB; Johnson RL; Nair VD; Mishra RK
J Pharmacol Exp Ther; 2005 Dec; 315(3):1228-36. PubMed ID: 16126839
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG): a review.
Mishra RK; Chiu S; Chiu P; Mishra CP
Methods Find Exp Clin Pharmacol; 1983; 5(4):203-33. PubMed ID: 6136640
[No Abstract] [Full Text] [Related]
[Next] [New Search]
